Stocktoria
Anixa Biosciences Inc ANIX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1983-10-07
Anixa Biosciences Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $210,000 | $210,000 | — | $512,000 |
| R&D expense | $5.1M | $6.4M | $4.8M | $6.7M | $6.2M |
| Operating income | -$11.7M | -$13.8M | -$11.0M | -$13.9M | -$13.1M |
| Net income | -$10.9M | -$12.6M | -$9.8M | -$13.6M | -$13.0M |
| EPS (diluted) | $-0.34 | $-0.39 | $-0.32 | $0.45 | — |
| Operating cash flow | -$7.2M | -$7.3M | -$6.2M | -$6.5M | -$4.9M |
| Cash & equivalents | $1.2M | $1.3M | $915,000 | $12.4M | $29.1M |
| Total assets | $16.1M | $21.6M | $25.5M | $30.4M | $36.3M |
| Total liabilities | $2.1M | $2.7M | $2.2M | $2.2M | $1.5M |
| Shareholders' equity | $15.2M | $20.0M | $24.3M | $29.0M | $35.4M |
Source: SEC EDGAR filings · CIK 0000715446 · as of 2025-10-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.